Heart and Vascular Research
Diabetes & Heart Failure Treatment Study
The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
AGE: 18 – 75 years old
GENDER: All
HEALTHY PARTICIPANTS: No
GENDER: All
HEALTHY PARTICIPANTS: No
TYPE: Interventional Study
CONDITION: Heart Disease, Diabetes
CONDITION: Heart Disease, Diabetes
LOCATION: University Hospitals Cleveland Medical Center
Learn More About This Research Study
For more information, please contact Ann Dever at 216-286-5038 and leave a message or complete the online form below.
Study Purpose
The purpose of this research this study is to investigate the effectiveness of ertugliflozin (a pill that lowers glucose levels) therapy to alter the heart’s metabolism to positively impact heart health and function in treating subjects with a type of chronic (long term) heart failure (HF) called heart failure with preserved ejection fraction (HFpEF).
Who Can Participate
Individuals between 18 and 75 years old who have not been hospitalized for heart failure within 6 months and has a BMI greater than 29 but less than 42 may be eligible for this study.